Abstract

Immunological activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases. Pharmacological studies using the recently discovered DP₁ and CRTH2 antagonists combined with genetic analysis support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy. This Review focuses on the emerging roles that DP₁ and CRTH2 (also known as DP₂) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state. We also discuss recent progress in the discovery and development of selective antagonists of these receptors.

Author affiliations

1. Oxagen Limited, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY, UK.
2. National Heart and Lung Institute Clinical Studies Unit, Royal Brompton Hospital, Fulham Road, London SW3 6HP, UK.

Correspondence to: Roy Pettipher¹ Email: r.pettipher@oxagen.co.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.